Jade BiosciencesJBIO
Recorded

Jade Biosciences 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration25 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Vamil DivanBiopharma Analyst

I think we're ready to get a start. Everyone joining us both for the Guggenheim Healthcare Innovation Conference, also for this session that we have with Jade Biosciences. I'm Vamil Divan, one of the biopharma analysts here, joined on the stage by Arseniy Yusupov. From the Jade side, we have Brad Dahms, and then to his side, Ed Conner, the CMO. Thank you both so much for joining us. Obviously, a lot going on with the Jade story, so great to dive into it today. Maybe I'll just turn it to you first for the investors who are maybe less familiar with Jade, just a little bit of background of the story, how you've gotten to where you are now, and then we'll dive into your programs.

Brad DahmsCFO

Yeah, absolutely. Thanks, Vamil, Arseniy, and Guggenheim for having us. It's been a busy conference. I think we're back-to-back from 8:00 to 5:00, so love to see it, but glad we're approaching the end of the day here. Jade is a company focused on autoimmune diseases. We were the fourth company that was founded with assets from Paragon Therapeutics, which the investor community is probably familiar with. They discovered Apogee, Oruka, Spyre before us, and I think they're on their like ninth company or something now. I've lost count. But again, we're focused on autoimmune diseases with rights to three assets. JADE101 is our lead program. It's an anti-APRIL monoclonal antibody, initially being developed for the treatment of IgAN, really solving for two key limitations that we saw, one being potency, so it's a femtomolar binder to APRIL, and then also extending the half-life.

Brad DahmsCFO

We have the YTE modification in the Fc for an extended half-life, which we believe supports a Q12 week dosing interval as informed by our phase I results, which we disclosed in June. In that program, we initiated our phase II in May with data coming in Q2 2027. We've also guided that we will initiate our registrational phase III this quarter, so it's been a very busy year for us on the JADE101 front. Second asset is JADE201. It's an afucosylated anti-BAFF-R monoclonal antibody following in the footsteps of a Novartis program called ianalumab. Has a dual mechanism of action, afucosylated for enhanced ADCC, so deep and rapid B cell depletion, but also by hitting the receptor, you can get into tissues where effector cells such as NK cells are sparse.

Brad DahmsCFO

Also by blocking the receptor, you're preventing this BAFF compensatory response where you see B cell repopulation as a response to BAFF inhibition by hitting the ligand, for example. So really excited about that program. Initiated a phase I in RA in May of this year with data from that study also coming in 2027. Finally, we have JADE301, which we recently disclosed. It's an anti-interferon beta monoclonal antibody initially being studied in dermatomyositis. We'll initiate the phase I healthy volunteer trial also this quarter, and then also we'll have data from that program in the second half, in that case, of 2027.

Brad DahmsCFO

And that's really leveraging some of the best-in-disease clinical activity we saw with the Pfizer program called dazukibart, where they saw a very significant reduction in TIS in their phase II. Importantly, they saw a very increase in TIS in their phase II, which is predominantly the muscle component, but where they also saw a really effective skin component where they saw this reduction in CDASI, which is the measure of the cutaneous disease component of about 16 points, which is numerically higher than anything we've seen in the class. Unfortunately, that drug is dosed IV. We believe that we're starting with sub-Q with higher bioavailability, and so have a really good path to best-in-disease clinical activity in that exciting indication. As of June 30, we had $461 million in cash with runway into the fourth quarter of 2028.

Vamil DivanBiopharma Analyst

Okay. That's a great overview, so thanks for that. Why don't we dive into 101 first, and then I'll have Arseniy jump in more on 201 and 301. Before we get to 101 and kind of the progress you've made there, obviously a lot of developments in the IgAN space more broadly, so maybe you can just talk about how you see this IgAN marketplace sort of evolving going forward, and then we'll talk about the place 101 might have in there.

Brad DahmsCFO

Yeah. Maybe I'll speak commercially and then pass it over to you for clinical. Yeah, we've been really impressed with the launch so far of sibeprenlimab. I think I checked Visible Alpha in like December of last year. I remember seeing something like consensus peak sales of something like south of $100 million, and that drug's on its way to doing $400 million this year, so really compelling commercial opportunity. They've continued to show really good clinical benefit as measured by obviously the proteinuria reductions, but two-year eGFR stabilization as well as good data that they demonstrated on hard kidney outcomes. We think that it is our belief that sibeprenlimab will be the sort of standard of care.

Brad DahmsCFO

We've also seen really positive updates to the KDIGO guidelines and sort of positioning the APRILs as the sort of first line of therapy in combination with some of the generic drugs like the ACE inhibitors and ARBs and things like that. Ed, if you want to speak.

Ed ConnerCMO

Yeah, on the clinical side too, there's been huge excitement about the program. We're very fortunate. We have a lot of ex-Chinook folks at Jade. They developed zigakibart, and so they know all the players in the IgAN space. Fortunate to have a rock star team on the operations side as well, so a lot of enthusiasm about the phase III initiating this quarter, really with the know-how to conduct a global study. Have met with many, many investigators across the globe who are very, very excited to get this study up and running.

Vamil DivanBiopharma Analyst

Okay. And you touched on this a little bit up front, but just sort of with sibeprenlimab on the market now, TRUTAKNA also on the market now as an APRIL-BAFF, sort of how do you see JADE101 setting itself apart from the other APRIL agents here.

Brad DahmsCFO

Yeah. I think we have to just kind of take a step back and look at what does an IgAN patient look like? These patients are It's kind of a unique disease where it's a very serious disease. If you did nothing, I mean, you would die of kidney failure, right? You would go into end-stage kidney disease. Obviously, you would get a transplant, we would hope, before that. But there hasn't really been a disease-modifying therapy the way that the B-cell modulators have shown with eGFR stabilization out to two years. We do think that the KDIGO guidelines, as I was alluding to before, because they call for these ambitious proteinuria targets, the reason they call for these ambitious proteinuria targets is because proteinuria is the best surrogate for long-term eGFR.

Brad DahmsCFO

Obviously, nobody's running a 10-year clinical trial, but nephrologists commonly treat to proteinuria because they know that lower proteinuria means more likely to have long-term stable kidney function. We do think that all these drugs are going to stabilize eGFR over the short term. The question is, can you get patients to a more ambitious proteinuria target that are in line with the KDIGO guidelines of 0.5 grams per day, preferably below 0.3, as outlined in the guidelines. We also think that safety is critical for the same reason. Again, these are young, otherwise healthy patients. So we think that having a selective anti-APRIL, which has shown really good clinical activity without hitting the sort of broader B-cell compartment, is desired specifically for IgAN. Then finally, the convenience side, and we would sort of overemphasize this.

Brad DahmsCFO

There's a lot of talk about convenience and sort of auto-injectors and volume of injection, et cetera, things like that. All of the companies that are out there, either with approved drugs or soon to be approved drugs, talking about convenience a lot. Obviously, the hallmark of convenience is how frequently or infrequently you're taking the drug. We were able to show in our phase I that we have confidence in a Q12-week dosing interval, which would basically be a third of the number of doses of the approved agent sibeprenlimab and the likely soon to be approved povetacicept. You mentioned TRUTAKNA, that's given an auto-injector weekly, so we obviously feel differentiated from that as well.

Vamil DivanBiopharma Analyst

Okay. Then, so maybe you guys are moving quickly, so obviously looking to get the phase III started here soon, get phase II data, interim data next year. Maybe you can walk through the phase III design and how you're planning on structuring that, especially with all the sort of developments in the space and new therapies entering.

Ed ConnerCMO

Yeah, so the phase III design we're very pleased with. It's informed by the National Kidney Foundation Consortium that really looked at the fact that given how potent these agents are, having patients on placebo for two years really isn't acceptable anymore because they're losing kidney function. I think some very attractive parts of our phase III, and the reason why investigators are excited about participating is it's randomized two to one, so two-thirds chance that you get the active drug. It's open label for one year, and that's when we do the analysis that we would ultimately end up filing. Then there's an open label component for 48 weeks after that. Again, patients would be two to one active for that first year, and then they would all go to drug in that second year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day